Prevalence and clinical correlates of bronchoreversibility in severe emphysema
- PMID: 19926748
- DOI: 10.1183/09031936.00052509
Prevalence and clinical correlates of bronchoreversibility in severe emphysema
Abstract
Chronic obstructive pulmonary disease (COPD) exhibits airflow obstruction that is not fully reversible. The importance of bronchoreversibility remains controversial. We hypothesised that an emphysematous phenotype of COPD would be associated with decreased bronchoreversibility. 544 patients randomised to the medical arm of the National Emphysema Treatment Trial formed the study group. Participants underwent multiple measurements of bronchoreversibility on a mean of four sessions over 1.91 yrs. They were also characterised by measures of symptoms, quality of life and quantitative measures of emphysema by computed tomography. Mean baseline forced expiratory volume in 1 s (FEV(1)) in this patient population is 24% predicted. 22.2% of patients demonstrated bronchoreversibility on one or more occasions using American Thoracic Society/European Respiratory Society criteria. Few patients (0.37%) had bronchoreversibility on all completed tests. Patients who demonstrated bronchoreversibility were more likely to be male, and have better lung function and less emphysema. 64% of patients demonstrated large (> or =400 mL) changes in forced vital capacity (FVC). In a severe emphysema population, bronchoreversibility as defined by change in FEV(1) is infrequent, varies over time, and is more common in males and those with less severe emphysema. Improvements in FVC, however, were demonstrated in the majority of patients.
Comment in
-
Bronchodilator testing: an endless story.Eur Respir J. 2010 May;35(5):952-4. doi: 10.1183/09031936.00003410. Eur Respir J. 2010. PMID: 20436170 No abstract available.
-
Assessment of bronchoreversibility in severe emphysema.Eur Respir J. 2010 Oct;36(4):972; author reply 973. doi: 10.1183/09031936.00070010. Eur Respir J. 2010. PMID: 20889470 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
- N01HR76113/HR/NHLBI NIH HHS/United States
- N01HR76104/HR/NHLBI NIH HHS/United States
- N01HR76105/HR/NHLBI NIH HHS/United States
- K23 HL68713/HL/NHLBI NIH HHS/United States
- N01HR76110/HR/NHLBI NIH HHS/United States
- R01 HL082480/HL/NHLBI NIH HHS/United States
- N01HR76119/HR/NHLBI NIH HHS/United States
- N01HR76109/HR/NHLBI NIH HHS/United States
- N01HR76116/HR/NHLBI NIH HHS/United States
- N01HR76107/HR/NHLBI NIH HHS/United States
- N01HR76102/HR/NHLBI NIH HHS/United States
- N01HR76118/HR/NHLBI NIH HHS/United States
- N01HR76115/HR/NHLBI NIH HHS/United States
- N01HR76111/HR/NHLBI NIH HHS/United States
- N01HR76114/HR/NHLBI NIH HHS/United States
- N01HR76103/HR/NHLBI NIH HHS/United States
- K24 HL04212/HL/NHLBI NIH HHS/United States
- R0-1 HL56309/HL/NHLBI NIH HHS/United States
- N01HR76108/HR/NHLBI NIH HHS/United States
- K24 HL004212/HL/NHLBI NIH HHS/United States
- N01HR76106/HR/NHLBI NIH HHS/United States
- N01HR76112/HR/NHLBI NIH HHS/United States
- N01-HR76101/HR/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical